论文部分内容阅读
大剂量阿糖胞苷单独或与其它药物联合治疗难治性急性非淋巴细胞白血病(简称急非淋)缓解率在15～70％,中数缓解期为3—10个月。然而这些方案毒性较高,有20～30％左右的患者早期死亡。作者报告了用中剂量阿糖胞苷(500mg/m~2)与胺苯吖啶(AMSA)联合治疗37例预后差的急非淋患者的疗效。 37例患者中13例系原发性耐药患者;19例是第一次复发;5例为慢粒急变患者。复发的患者先前均用过DAT方案化疗,且接受过一个疗程的巩固治疗,但未维持治疗。原发性耐药是指一个疗程化疗后
High-dose cytarabine alone or in combination with other drugs for the treatment of refractory acute non-lymphocytic leukemia (referred to as acute non-lymphocin) remission rate of 15 to 70%, the median remission period of 3 to 10 months. However, these regimens are highly toxic, with about 20 to 30% of patients dying early. The authors reported the efficacy of the combination of mid-dose cytarabine (500 mg/m~2) and amine benzoquinone (AMSA) in the treatment of 37 patients with acute non-lymphocin with poor prognosis. Of the 37 patients, 13 were primary drug-resistant patients; 19 were the first relapse; 5 were patients with chronic granuloma. The relapsed patients had previously received DAT chemotherapy and received a course of consolidation therapy but did not maintain treatment. Primary drug resistance refers to a course of chemotherapy